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ToleranceBioﬁlms are communities of microbial cells that are attached to
each other and/or a surface, and are embedded in an extracellular
matrix produced by the bacteria and/or derived from the host.
Treatment of bioﬁlm-related infections is difﬁcult, as sessile mi-
croorganisms show reduced antimicrobial susceptibility as a result
of various resistance and tolerance mechanisms [1].
In the medical bioﬁlm ﬁeld, standardization or guidance is
important for diagnosis, determining the efﬁcacy of antibiotics and
the ability to prevent or reduce bioﬁlm formation on indwelling
devices. Guidelines for diagnosing bioﬁlm infections [2] and stan-
dardized methods to assess the efﬁcacy of surface disinfection are
available [3]. However, parameters that predict the therapeutic
success of antibiotics are determined using planktonic bacteria [4]
and therefore fail to take into account important local pharmaco-
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(MBIC) and the minimum bioﬁlm eradication concentration
(MBEC) are utilized to determine antibiotic efﬁcacy against bio-
ﬁlms. MBIC and MBEC values are typically much higher than the
minimum inhibitory and minimum bactericidal concentrations,
respectively [5]. It has been suggested that treatment decisions
should be based on MBIC or MBEC values [6]. However, the rela-
tionship between intrinsic activity towards planktonic and sessile
cells is complex, and currently there is insufﬁcient evidence to
recommend choosing antibiotics on the basis of bioﬁlm suscepti-
bility testing [7]. For example, MBIC values did not predict clinical
success for the treatment of catheter-related bloodstream in-
fections due to enterococci [8], and superiority of treatment based
on bioﬁlm susceptibility testing over conventional susceptibility
testing could not be demonstrated in two clinical trials addressing
treatment of Pseudomonas aeruginosa respiratory tract infections in
cystic ﬁbrosis (CF) patients [7].
Here we discuss the issue whether standard methods for anti-
biotic susceptibility testing of microbial bioﬁlms should be intro-
duced in clinical practice to guide decisions about treatment, and
we discuss their value in the regulatory pathway of approval of
antibioﬁlm products or devices, i.e. products or devices that pre-
vent or reduce bioﬁlm formation and/or allow (partial) eradication
of established bioﬁlms (Fig. 1).
Most of our knowledge regarding bioﬁlm tolerance is derived
from in vitro assays. An important question is whether these in vitro
tests are predictive of the in vivo situation and can be used to help
guide clinical therapy and to evaluate novel antimicrobial com-
pounds. In vitro, bioﬁlm formation occurs in a sequence of distinct
events (attachmentdmaturationddispersal), while in vivo, this
sequence of events might not apply. Most in vitromodels are poorly
representative of an infection site: in vivo bioﬁlms are not exposed
to a continuous ﬂow of freshmedia, and they are not attached to an
artiﬁcial surface but are embedded in tissues, in the thick mucus of
the CF lung or between the implant and the tissue [2]. In vivo
bioﬁlms occur typically as small aggregates (5e200 mm inblished by Elsevier Ltd. All rights reserved.
Fig. 1. Pros and cons of in vitro standardized bioﬁlm models.
T. Coenye et al. / Clinical Microbiology and Infection 24 (2018) 570e572 571diameter) embedded in host material with a secondary matrix on
top of or intermixed with the bacterial matrix, making treatment
aimed at dispersal and/or killing even more problematic. Sessile
bacteria are often not exposed to ﬂow in vivo, and despite their low
metabolic activity, they still elicit an inﬂammatory response [9].
In principle, the susceptibility of an in vivo bioﬁlm does not
differ from that of an in vitro bioﬁlm, but the access of the antibi-
otics to the bioﬁlm is different: while an antibiotic can be added
directly to the bioﬁlm in vitro, in vivo the antibiotic must ﬁrst reach
the bioﬁlm. These bioﬁlms are often localized in deep tissues, with
profound differences in drug access between different types of
infections (e.g. chronic wound vs. implant). A second issue is that
bacteria in bioﬁlms are extremely tolerant to antibiotics, and higher
doses and longer exposure times are required to kill bioﬁlms than
planktonic cells [5,10,11]. The antibiotic concentration required to
achieve inhibition and/or eradication of bioﬁlm-associated bacteria
is often beyond what is achievable in vivo if administered system-
ically (although effective concentrations can sometimes be ach-
ieved locally, e.g. using inhaled antibiotics in CF patients or when
using antibiotic-coated beads in orthopaedic infections) [11].
Consequently, testing bacterial isolates from chronic infections for
bioﬁlm susceptibility towards antibiotics in vitro is not particularly
helpful to guide clinical decisions because the necessary concen-
tration cannot be achieved in the patient.
Progress has been made in developing laboratory bioﬁlm
models that are more representative of the situation in a patient
(e.g. in the context of chronic wound infections [12] and CF [13]),
but studies establishing the clinical validity of these models are still
lacking. However, even in relevant bioﬁlm models, activity of an-
tibiotics is often only observed at concentrations that cannot be
reached in vivo. The implementation of such models is technically
demanding and may not be within the reach of every clinical
microbiology laboratory. Despite its limitations, susceptibility
testing on planktonic isolates (minimum inhibitory concentration
determination) is useful for measuring antibiotic resistance, and
once resistance is identiﬁed, the use of these antibiotics should be
avoided for the treatment of that particular infection. This ensures
that the antibiotics used are likely to have an effect on the actively
growing (less dormant) bacteria in the infection and suppress their
spread from the site of infection.When it comes to regulatory approval of antibioﬁlm devices
and treatments, standardized bioﬁlm testing is essential [3]. A
company that wants to bring a new device or drug to market must
register it with the regulatory agencies. These agencies issue
guidelines that describe the pathway that must be followed to take
the product through the validation process. Many guidelines
require in vitro data that demonstrate the drug and/or device's
effectiveness, and a well-designed in vitro standard method is a
critical and necessary part of this regulatory pathway. Data
collected using a standardmethod allow regulators to assess a new
device and/or drug and compare its performance to existing
technology on the market. A standard method allows companies
to demonstrate that the new drug or device provides statistically
equivalent results to approved technologies and provides moti-
vation for moving forwards with a costly clinical trial, where the
question whether the device and/or drug is clinically useful is
deﬁnitively answered.
In vitro methods are often criticized for not correctly modeling
the in vivo infection because of the simplifying assumptions made.
However, standard methods contain a ‘signiﬁcance and use’ section
that provides guidance on how the test results should be inter-
preted. A standard microbiologic method should not be used for an
application that the method was never designed to test (e.g. a zone
of inhibition test does not provide much information on how an
antimicrobial catheter will perform in vivo, but rather provides an
indication if the active compound diffuses into agar at a concen-
tration that prevents microbial growth). It is thus not surprising
that the use of a product ‘veriﬁed’ with a standard method that was
designed for a different application results in clinical data that are
not in line with the in vitro test results. In addition, a standard
method [14] does not need to address every parameter, just the
most inﬂuential ones, as too much complexity results in the po-
tential for greater variability in the data. Besides their role in the
process of regulatory approval, standardized methods can play an
important role in increasing our understanding of the basic biology
of bioﬁlms and the mechanisms involved in bioﬁlm tolerance.
Indeed, comparison between different studies is often hampered by
a lack of standardization, and standardized methods are an
important tool to screen large libraries for potential compounds
with antibioﬁlm activity.
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susceptibility tests will frequently yield results that are poorly
representative of the activity of the antibiotic against the bioﬁlm
in vivo because of profound differences between the two types of
bioﬁlms. There is currently no evidence that introducing stan-
dardized bioﬁlm susceptibility testing in clinical practice would
improve patient outcome. However, we are convinced that stan-
dardized methods are valuable for research purposes and in the
process of regulatory approval (Fig. 1). Whether the development
and implementation of more relevant, peer-reviewed and statisti-
cally validated methods will lead to better approaches to treating
bioﬁlm infections should be the subject of future research.
We hope this commentary will stimulate efforts in elucidating
factors affecting antibiotic activity against bioﬁlms in vivo, thereby
helping the development of in vitro assays for testing antibioﬁlm
drugs that more appropriately mimic the in vivo bioﬁlm.
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